STERIS PLC
STE
ISIN IE00BFY8C754 / Valor 47027903
STERIS PLC
UMushroom community rating:
About company
STERIS PLC, originally founded as Innovative Medical Technologies in Ohio in 1985 and renamed in 1987, has grown into a leading global provider in infection prevention and procedural products and services. With a history enriched by acquisitions, such as the American Sterilizer Company, STERIS now boasts a workforce of approximately 16,000 associates and operates in over 100 countries. The company's portfolio spans a broad range of innovative capital equipment, including sterilizers, washers, surgical tables, and lights, alongside equipment management systems and connectivity solutions aimed at integrating operating rooms. Additionally, STERIS offers a variety of consumable products, from detergents to gastrointestinal endoscopy accessories and dental instruments. Its service offerings are comprehensive, covering equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services, and off-site reprocessing. Central to STERIS's mission is its commitment to supporting patient care by focusing on infection prevention, thereby aiding healthcare, life sciences, and dental sectors in creating healthier and safer environments.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (29.08.2026):
STERIS PLC's fiscal 2027 first quarter (ended June 30, 2026) showed solid top-line growth and improved adjusted earnings: total revenue rose 7% to $1.5 billion (constant‑currency organic growth 6%), as‑reported diluted EPS was $2.04 and adjusted EPS was $2.59, and the company reiterated full‑year guidance while announcing a targeted restructuring tied to a new formulated chemistries Center of Excellence in North Carolina.
Revenue & organic growth
Total revenue was $1.50 billion, up 7% versus Q1 FY2026; constant‑currency organic revenue growth was 6%.
Earnings
Net income was $200.1 million, or $2.04 per diluted share (vs. $177.4M / $1.79 prior year). Adjusted net income was $253.4 million, or $2.59 per diluted share (vs. $231.2M / $2.34 prior year).
Healthcare segment
Healthcare revenue grew 8% to $1.05 billion (service +10%, consumables +9%, capital equipment +1%). Healthcare operating income was $260.2 million, driven by volume, price and productivity gains, partially offset by inflation and tariffs.
Applied Sterilization Technologies (AST)
AST revenue was $297.6 million, up 6% (service +6%, capital equipment down 13%). Segment operating income was $142.9 million, aided by pricing but partially offset by higher depreciation and labor.
Life Sciences
Life Sciences revenue increased 9% to $146.7 million (capital equipment +17%, consumables +8%, services +2%). Operating income rose to $61.8 million.
Cash flow
Net cash provided by operations was $367.1 million (down from $420.0 million), and free cash flow was $279.6 million (down from $326.5 million), largely due to a smaller working capital benefit in the quarter.
Restructuring — Center of Excellence
STERIS announced a consolidation of formulated chemistries to a new North Carolina Center of Excellence, expecting pre‑tax restructuring charges of ~$55–70 million (cash ~$40–50M; non‑cash ~$15–20M), with completion anticipated by fiscal 2030; these charges will be excluded from adjusted earnings measures.
Fiscal 2027 outlook
The company reaffirmed prior guidance: as‑reported revenue growth 7–8%, constant‑currency organic growth 6–7%, adjusted EPS $11.10–11.30. Capital expenditures guidance was raised to about $450 million (from $375M) and free cash flow is now expected to be about $800 million (prior $850M).
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
22391 M
Market cap (USD)
558,506
Daily traded volume (Shares)
206.18 / 203.59
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
